A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex

Cancer Research

Volumn 61, Issue 9, 2001, Pages 3653-3659

  Cooke, S P ^a   Boxer, G M ^a   Lawrence, L ^a   Pedley, R B ^a   Spencer, D I R ^a   Begent, R H J ^a   Chester, K A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN LL4; RECOMBINANT ANTIBODY; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL HYPOXIA; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; COLORECTAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035328576     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
2. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
3. Vascular permeability factor, an endothelial cell mitogen related to PDGF
4. Vascular endothelial growth factor is a secreted angiogenic mitogen
5. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
6. Molecular and biological properties of vascular endothelial growth factor
7. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing antibodies or by VEGF receptor tyrosine-kinase inhibitors
8. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
9. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
10. Vascular endothelial growth factor as a marker of tumor endothelium
11. The frns-like tyrosine kinase, a receptor for vascular endothelial growth factor
12. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
13. Receptors for the factors of VEGF family
14. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
15. Antibody-directed enzyme prodrug therapy for cancer: Its theoretical basis and application
16. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor α
17. Construction and expression of antibody-tumor necrosis factor fusion proteins
18. Cytotoxic and anti-tumor activity of recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells
19. A genetically engineered single-chain Fv/TNF molecule possesses the anti-tumor immunoreactivity of Fv as well as the cytotoxic activity of tumor necrosis factor
20. Recombinant antibody constructs in cancer therapy
21. Man-made antibodies
22. Making antibodies by phage display technology
23. Optimization of primer sequences for mouse sFv repertoire display library construction
24. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension
25. Multi-chain proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
26. By-passing immunization. Human antibodies from V-gene libraries displayed on phage
27. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography
28. Production and tumor-binding characterisation of a chimeric anti-CEA Fab expressed in Escherichia coli
29. Radioimmunolography: A tool for relating antigen concentration to clinical outcome
30. Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril
31. 131I anti-CEA antibody in a colonic xenograft model
32. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
33. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors
34. Carcinoembryonic antigen is anchored to membranes by covalent attachment to a glycosylphoshatidylinositol moiety: Identification of the ethanolamine linkage site
35. A comparative study, using the Linear Quadratic Model, of the effectiveness of radiolabelled antibodies for radioimmunotherapy in a colorectal xenograft model
36. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
37. Reducing renal acretion of radiolabeled antibody fragments and peptides: Improvement of therapeutic efficacy by overcoming nephrotic potential? A review
38. A comparative study of the expression patterns for VEGF, VEGF-B and VEGF-C in the developing and adult mouse